PROJECT 2 During the last funding period, we demonstrated that programmable pump delivery of GDNF promotes improvements in motor and nigrostriatal dopamine (DA)functions in nonhuman primate models of Parkinson's disease (PD). In the proposed studies, Project 2 will use behavioral and functional magnetic resonance imaging (fMRI) methods to determine conditions to further enhance GDNF actions on motor arid DA functions in MPTP-lesioned rhesus monkeys, which best simulate the human parkinsonian state. In conjunction with Projects 1 & 3, Project 2 will determine if combined putamenal and nigral delivery of GDNF, via programmable pumps and intraparenchymal catheters, will produce better behavioral recovery of the nigrostriatal pathway than single-site putamenal delivery alone. Project 2 will also investigate if chronic, intraparenchymal delivery of GDNF will more completely, restore motor and DA functions in MPTP-lesioned animals expressing milder, but stable parkinsonism versus severely impaired animals. In Project 2, the animals will be quantitatively characterized with apomorphine and levodopa/carbidopa, pre- and post-GDNF administration. To this end, we will use a variety of behavioral measurements, including: 1) an automated video-tracking system for analyzing whole body movements, 2) an automated hand-retrieval task for evaluating fine hand/coarse arm movements, and 3) a nonhuman primate rating scale for evaluating behavioral features characteristic of PD: bradykinesia, rigidity, posture, balance and tremor. In addition to behavioral testing, Project 2 will use fMRI techniques to noninvasively and simultaneously measure apomorphine-evoked blood oxygen level-dependent (BOLD) changes in basal ganglia functions of alert rhesus monkeys, pre- and post-GDNF administration. Collectively, these studies should contribute to an improved mechanistic understanding of the effects of chronic GDNF treatment on the nigrostriatal DA system in nonhuman primates and improved approaches for the treatment of PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS039787-09
Application #
7665347
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
9
Fiscal Year
2008
Total Cost
$167,603
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Stenslik, M J; Evans, A; Pomerleau, F et al. (2018) Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques. J Neurosci Methods 303:30-40
Stenslik, Mallory J; Potts, Lisa F; Sonne, James W H et al. (2015) Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. J Neurosci Methods 251:120-9
Fan, X T; Zhao, F; Ai, Y et al. (2014) Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency. Brain Res 1552:34-40
Fuqua, Joshua L; Littrell, Ofelia M; Lundblad, Martin et al. (2014) Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro. Peptides 54:1-8
Stephens, Michelle L; Williamson, Anne; Deel, Megan E et al. (2014) Tonic glutamate in CA1 of aging rats correlates with phasic glutamate dysregulation during seizure. Epilepsia 55:1817-25
Littrell, Ofelia M; Granholm, Ann-Charlotte; Gerhardt, Greg A et al. (2013) Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF. Pharmacol Biochem Behav 104:10-9
Littrell, O M; Fuqua, J L; Richardson, A D et al. (2013) A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides 47:43-9
van Bregt, Daniel R; Thomas, Theresa Currier; Hinzman, Jason M et al. (2012) Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat. Exp Neurol 234:8-19
Littrell, Ofelia M; Pomerleau, Francois; Huettl, Peter et al. (2012) Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice. Neurobiol Aging 33:427.e1-14
Hascup, Kevin N; Bao, Xiaodong; Hascup, Erin R et al. (2011) Differential levels of glutamate dehydrogenase 1 (GLUD1) in Balb/c and C57BL/6 mice and the effects of overexpression of the Glud1 gene on glutamate release in striatum. ASN Neuro 3:

Showing the most recent 10 out of 63 publications